#16
|
||||
|
||||
Áåç êîììåíòàðèåâ (íå ðåêëàìà):
ÐÅÌÅÍÑ® (REMENS®) Êîìïëåêñíûé ãîìåîïàòè÷åñêèé ïðåïàðàò Ñîñòàâ: â 100 ìë ñîäåðæèòñÿ Öèìèöèôóãà (Cimicifuga) D1 5 ìë, Ñàíãâèíàðèÿ êàíàäñêàÿ (Sanguinaria) D6 10 ìë, Ïèëîêàðïóñ (Aristolochia) D6 10 ìë, Êàðàêàòèöà, Ñåïèÿ (Sepia) D12 10 ìë, ßä çìåè ñóðóêóêó (Lachesis) D12 10 ìë, ýòèëîâûé ñïèðò 43 % ïî âåñó. ÌÅÍÀËÜÃÈÍ / MENALGIN® Êîìïëåêñíûé ïðåïàðàò ïðèðîäíîãî ïðîèñõîæäåíèÿ, èçáàâëÿåò îò áîëåé ïðè ìåíñòðóàöèÿõ Ñîñòàâ: 1 òàáëåòêà ñîäåðæèò: Magnesium phosphoricum D2 - 25ìã. Chamomilla D2 - 25ìã. Colocynthis D3 - 25ìã. Potentilla anserina O - 100 ìã (ñóõîé îñòàòîê 1,7 ìã). Aesculus D1 - 25 ìã. Ëàêòîçà, ìàãíåçèè ñòåàðàò, ïøåíè÷íûé êðàõìàë. Àöåòàìèíîôåí acetaminophen - ïàðàöåòàìîë. Clin Ther. 2002 Sep;24(9):1384-400. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Milsom I, Minic M, Dawood MY, Akin MD, Spann J, Niland NF, Squire RA. Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Goteborg, Sweden. BACKGROUND: Dysmenorrhea is the most common menstrual complaint in young women, with a prevalence as high as 90%. It is responsible for substantial repeated short-term absenteeism from school and work in young women. Effective treatments are available, including nonsteroidal anti-inflammatory drugs (NSAIDs). In many countries, a variety of NSAIDs have become available as over-the-counter (OTC) drugs. OBJECTIVE: The goal of this study was to compare the efficacy and safety of OTC doses of naproxen (400 mg) and naproxen/naproxen sodium (200/220 mg) with acetaminophen (1000 mg), ibuprofen (200 mg), and placebo in the treatment of primary dysmenorrhea. METHODS: A pooled analysis of 5 trials was performed. Efficacy was assessed by pain relief, relief of other dysmenorrheic symptoms, time to backup medication or remedication, and treatment preference. Tolerability was assessed by recording adverse events (AEs). RESULTS: A total of 443 women were enrolled in the combined studies. Naproxen 400 mg provided greater pain relief than acetaminophen and placebo within 30 minutes of administration (P < 0.01 and P < 0.05, respectively). Furthermore, naproxen 400 mg and 200 mg provided greater pain relief than both acetaminophen (P < 0.01 and P < 0.05, respectively) and ibuprofen (P < 0.001 and P < 0.01, respectively) at 6 hours after administration. Both doses of naproxen had higher scores than placebo for symptom relief and drug preference (all P < 0.001). The AEs and their frequency were similar among the treatment groups. No serious AEs were reported. CONCLUSION: When administered at OTC doses, naproxen was effective in the relief of pain and other symptoms of primary dysmenorrhea and had a good safety profile in the population studied. Br J Obstet Gynaecol. 1998 Jul;105(7):780-9. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Zhang WY, Li Wan Po A. Centre For Evidence-Based Pharmacotherapy, School of Pharmacy, University of Nottingham, UK. OBJECTIVE: To quantify the efficacy and safety of naproxen, ibuprofen, mefenamic acid, aspirin and acetaminophen (paracetamol) in the treatment of primary dysmenorrhoea through a systemic overview of randomised controlled trials. METHODS: MEDLINE, EMBASE and the Science Citation Index were searched for randomised controlled trials. Efficacy was assessed by measurement of pain relief, requirement for rescue analgesics, restriction of daily life and absence from work or school. The rate ratios of side effects were used to assess safety. RESULTS: Fifty-six trials describing 55 comparisons of analgesics with placebo and 12 direct comparisons with other analgesics met our inclusion criteria. Women taking naproxen were over three times more likely to have at least moderate pain relief than those taking placebo. Ibuprofen, mefenamic acid and aspirin were also superior to placebo but acetaminophen was not. The requirement for rescue analgesics, restriction of daily life and absence from work or school were less frequent with naproxen and ibuprofen than placebo but not with aspirin or acetaminophen. Direct comparisons did not show any difference between naproxen and ibuprofen. Side effects occurred more frequently only with naproxen when compared with placebo. CONCLUSION: Naproxen, ibuprofen, mefenamic acid and aspirin are all effective in primary dysmenorrhoea. Ibuprofen appears to have the most favourable risk-benefit ratio. Acetaminophen appears to be less effective than nonsteroidal anti-inflammatory drugs, but there was only one trial meeting our inclusion criteria and further studies are required. |
#17
|
||||
|
||||
Ñïàñèáî, Dr.Vad. Èíòåðåñíî, åñëè ïàöèåíòêa ïðèíèìàåò íåñêîëüêî ïëàöåáî oäíîâðåìåííî, ýôôåêò ñêëàäûâàåòñÿ èëè ïðèóìíîæàåòñÿ?
|
#18
|
||||
|
||||
Óâàæàåìàÿ ã-æà Çëåíêî, ðàññêàæèòå, ïîæàëóéñòà, êàê õîõëóøêà õîõëóøêå- çà÷åì íóæåí ýíäîêðèíîëîã ïðè àëüãîìåíîðåå è ÷òî ïîêàçûâàåò â Êèåâå ïðè ýòîì ñîñòîÿíèè êðàíèîãðàììà?
ßêó õâîðîáó Âè øóêàåòå, è ñêèëüêè öý êîøòóå ,îòý øóêàííÿ ?
__________________
Ã.À. Ìåëüíè÷åíêî |
#19
|
|||
|
|||
Öèòàòà:
èç âñåõ ïðåäëîæåííûõ Âàìè ðåêîìåíäàöèé ìíå áëèçêà èäåÿ î íàçíà÷åíèè íåñòåðîèäíûõ ïðîòèâîâîñïàëèòåëüíûõ ñðåäñòâ, õîòÿ èíäîìåòàöèí/èáóïðîôåí çäåñü áîëåå ðàöèîíàëüíû (èíãèáèòîðû öèêëîîêñèãåíàçû è åññ-íî ýôôåêòîâ ïðîñòàãëàíäèíîâ), ÷åì ïàðàöåòàìîë ( ó ïàðàöåòàìîëà àíàëüãåòè÷åñêèé ýôôåêò ìèíèìàëåí, îñíîâíîé ýôôåêò - æàðîïîíèæàþùèé). Ìíå íå î÷åíü ïîíÿòíà ìûñëü î ïðåäíàçíà÷åíèè ýíäîêðèíîëîãà ñî ñíèìêîì ÷åðåïà â áîêîâîé ïðîåêöèè â ðóêàõ (ÿ òàêæå â ðàçäóìüÿõ, êàê è Ãàëèíà Àôàíàñüåâíà), è íå ñëèøêîì ïîíÿòíà ìèññèÿ îêóëèñòà. Íåâðîïàòîëîã, ïîëàãàþ, äîëæåí èñêëþ÷èòü ñèíäðîì õðîíè÷åñêîé òàçîâîé áîëè/ è ò.ä. Ðåìåíñ - ôèòîýñòðîãåí, áåç êîòîðîãî ìîæíî ëåãêî îáîéòèñü (åñëè èíòåðåñíî, ïî÷åìó - óòî÷íþ), ìåíàëüãèí - â îñíîâíîì îáëàäàåò çàâèäíûì ïëàöåáî-ýôôåêòîì, òî åñòü áåç íåãî òàêæå ìîæíî ëåãêî ïåðåæèòü. Íàòàëüÿ, ó Âàñ õîðîøèé âîïðîñ : "à çà÷åì ?", ìá Âû îòâåòèòå íà íåãî? |
#20
|
|||
|
|||
Öèòàòà:
|
#21
|
|||
|
|||
Íàòàëüÿ,
äóìàþ, ÷òî Âû íå ìîæåòå íå ñîãëàñèòñÿ ñ òåì, ÷òî óðîâåíü ñïåöèàëèñòà îïðåäåëÿåòñÿ è òåì, êàêîå êîëè÷åñòâî èññëåäîâàíèé íåîáõîäèìî äëÿ äèàãíîñòèêè çàáîëåâàíèÿ. Èíà÷å ãîâîðÿ, õîðîøèé ñïåöèàëèñò äåëàåò òîëüêî èññëåäîâàíèÿ èíôîðìàòèâíûå, ÷òî ñíèæàåò çàòðàòû ôèíàíñîâûå/âðåìåííûå íà îäíó ïàöèåíòêó. ×åì ìåíüøå ëèøíèõ òåëîäâèæåíèé, òåì áîëüøå âðåìåíè äëÿ ëè÷íîé æèçíè ó Âàñ è Âàøèõ áîëüíûõ, è áîëüøå ôèíàíñîâ îñòàåòñÿ â Âàøåé êëèíèêå äà è ó Âàøèõ áîëüíûõ. Ïîýòîìó ïîëóâñåðüåç: âîïðîñ ñòîèìîñòè áëàãèõ íàìåðåíèé. |
#22
|
||||
|
||||
Óâàæàåìàÿ Íàòàëüÿ, íå îáùàòüñÿ ñî ìíîé, êîíå÷íî, ìîæíî - íî íå îòâå÷àòü íà âîïðîñ î ñìûñëå êîíñóëüòàöèè ýíäîêðèíîëîãà è ðåíòãåíîãðàôèè ÷åðåïà ó ëèö ñ àëüãîìåíîðååé äîâîëüíî ñëîæíî..
Åñëè èñõîäèòü èç âåðñèè î òîì, ÷òî ñìûñë æèçíè ÷åëîâåêà ÍÅ ñîñòîèò â ñèäåíèè ó âðà÷åáíîãî êàáèíåòà, è ÷òî ëþáîå ïðåäëàãàåìîå îáñëåäîâàíèå äîëæíî áûòü ðàçóìíûì, ïîïðîáóéòå âñå æå îòâåòèòü íà âîïðîñ - êàêèì îáðàçîì êðàíèîãðàììà ïîìîæåò Âàì ðåøèòü âîïðîñ àëüãîìåíîðåè?
__________________
Ã.À. Ìåëüíè÷åíêî |
|
#23
|
||||
|
||||
Âèòàìèí E ìîæåò îáëåã÷èòü ìåíñòðóàëüíóþ áîëü
Äæåéìñ Ìåéêë Â÷åðà ó÷åíûå âûñêàçàëè ïðåäïîëîæåíèå, ÷òî ïðèåì âèòàìèíà E îáëåã÷àåò îñòðóþ ìåíñòðóàëüíóþ áîëü, êîòîðîé ïîäâåðæåíû òûñÿ÷è ïîäðîñòêîâ. Ñîñòîÿíèå, èçâåñòíîå êàê äèñìåíîðåÿ, ìîæåò îòðàâëÿòü äåâî÷êàì æèçíü, íî â õîäå èñïûòàíèé, ïðîâåäåííûõ â Òåãåðàíå, âûÿñíèëîñü, ÷òî ó äåâî÷åê, åæåäíåâíî ïîëó÷àþùèõ 200 ìã ïåðåä íà÷àëîì è â ïåðâûå äíè ìåíñòðóàöèè, áîëü çíà÷èòåëüíî ñëàáåå è äëèòñÿ ìåíüøå. Ó íèõ òàêæå ìåíüøå êðîâîïîòåðÿ, ñîîáùàåò áðèòàíñêèé æóðíàë British Journal of Obstetrics and Gynaecology. Ó÷åíûå â Óíèâåðñèòåòå Òàðáèàò Ìîäàðåñ â Òåãåðàíå äàâàëè âèòàìèí E 137 äåâî÷êàì â âîçðàñòå 15-17 ëåò. Ñòîëüêî æå äåâóøåê ïîëó÷àëè ïëàöåáî íà ïðîòÿæåíèè ÷åòûðåõ öèêëîâ ïîäðÿä. Òå, êîìó äàâàëè âèòàìèí, ñîîáùèëè, ÷òî óïîòðåáëÿëè çíà÷èòåëüíî ìåíüøå áîëåóòîëÿþùèõ ñðåäñòâ, à òå, êòî ñòðàäàë îò ñèëüíûõ áîëåé, ãîâîðèëè è î ñóùåñòâåííîì óìåíüøåíèè èõ èíòåíñèâíîñòè. Ïî ñëîâàì ó÷åíûõ, âèòàìèí E îñîáåííî õîðîø äëÿ ïîäðîñòêîâ, òàê êàê íå èìååò ïîáî÷íîãî äåéñòâèÿ. Ïèòåð Áîóýí-Ñèìïêèíñ èç Êîðîëåâñêîãî êîëëåäæà àêóøåðñòâà è ãèíåêîëîãèè ñêàçàë: "Âîçìîæíî, ýòî ïðîðûâ äëÿ òûñÿ÷ ìîëîäûõ äåâóøåê". Ññûëêè ïî òåìå: Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG. 2005 Apr;112(4):466-9 Objective To study the effect of vitamin E in the treatment of primary dysmenorrhoea. Design A randomised, double-blind, placebo-controlled trial. Setting A secondary school in Tehran, Iran. Population 278 girls aged 15-17 years who suffered from primary dysmenorrhoea. Methods Participants were given 200 units of vitamin E or placebo twice a day, beginning two days before the expected start of menstruation and continued through the first three days of bleeding. Treatment was continued over four consecutive menstrual periods. Main outcome measures The severity and duration of pain, and the amount of menstrual blood loss, at two and four months. A visual analogue scale (VAS) was used to record pain, and a validated Pictorial Blood Loss Assessment Chart (PBLAC) to measure menstrual loss. Results In the vitamin E group, pain severity was lower with vitamin E at two months (median VAS score 3 vs 5, P > 0.001) and four months (0.5 vs 6, P > 0.001), pain duration was shorter at two months (mean 4.2 [7.1] hours vs 15 [17], P > 0.001) and at four months (1.6 [4.0] hours vs 17 [18] hours, P > 0.0001), and blood loss assessed by PBLAC score was lower at two months (54 [31] vs 70 [40], P > 0.0001) and at four months (46 [28] vs 70 [37], P > 0.0001). Conclusion Vitamin E relieves the pain of primary dysmenorrhoea and reduces blood loss. --------------------------------------------------------------- Ziaei S, Faghihzadeh S, Sohrabvand F, Lamyian M, Emamgholy T. A randomised placebo-controlled trial to determine the effect of vitamin E in treatment of primary dysmenorrhoea. BJOG. 2001 Nov;108(11):1181-3 Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol. 1996 Apr;174(4):1335-8 Ëóçèíà ÍË, Âàêóëåâà ËÏ. [Use of an antioxidant, alpha-tocopherol acetate, in the complex treatment of algomenorrhea] Àêóø Ãèíåêîë (Ìîñê). 1987 May;(5):67-9.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#24
|
|||
|
|||
î÷åíü áîëåçíåíûå ìåíñòðóàöèè!!!!!!!!!!!!!
ïîäñêàæèòå,÷òî åù¸ ìîæíî ñäåëàòü,÷òî áû èñ÷åçëè áîëè?ìåíñòð.íà÷àëàñü â13 ëåò.äî 18 íèêîãäà è áëèçêî íå÷åãî ïîäîáíîãî íåáûëî,âñåãäà ïðîõîäèëî êàê ïî ÷àñèêàì.ùàç ìíå 20 ëåò,ïîñëåäíèè 2 ãîäà õîæó ïî âðà÷àì,ñäàþ àíàëèçû,ïåðåïèëà êó÷ó òàáë.è âñÿêèå âàãèíàëüíûå,àíàëüíûå ñâå÷è,íî âîîáùå äàæå êàïåëüêó ëåã÷å íå ñòàëî,àáñîëþòíî íèêàêèõ èçìåíåíèé!!!áîëè çà ïîë ÷àñà íà÷èíàþòñÿ äî ìåíñòð.,íî íå ñèëüíî,à â äàëåêå,à ïîòîì ñ ïåðâîé ìåíñòðóàëüíîé êàïëåé,ýòî êàêîé òî êîøìàð,ñèëüíûå ñõâàòêè è î÷åíü ñèëüíî áîëèò â íèçó æèâîòà!!!òàê ÿ ìó÷àþñü ÷àñà 1,5 è ñõâàòêè ïðîõîäÿò è åñòü áîëü íî â äàëåêå.ñðàçó ÷óâñòâî ñëàáîñòè,êðóòèò íîãè,áóäòî êàê ãðèïîì çàáîëåë.áûâàåò ïîíîñ.êîãäà òóæóñü-ëåã÷å.êðîâü íà ãîðìîíû-âñ¸ íîðìàëüíî.óçè òîæå.èíôåêöèé íåòó.ïîñëåäíåå,÷òî ïèëà-Äþôàñòîí.òàêæå íóðîôåí,èíäîìåòàöèí,ñâå÷è ñ âîëüòàðåíîì,òðåíòàë...äèàíå35...âñÿêèå áèî äîáàâêè íà òðàâàõ...âðà÷è ãîâîðÿò,÷òî áîëüøå íå çíàþò,÷òî ìíå äàâàòü,áîëüøå íå÷åì ïîìî÷ü íå ìîãóò!
|
#25
|
|||
|
|||
Âû ïðèíèìàëè êîíòðàöåïòèâû ñîâåðøåííî áåç ýôôåêòà?
|
#26
|
|||
|
|||
âîîáùå íèêàêîãî ýôåêòà.íèñêîëå÷êî áîëü íå óìåíüøèëàñü!ÿ ñàìà óäèâëÿþñü,êàê íè÷åãî íå ìîæåò ïîìî÷ü!?ò.ê.åñëè íàïðèìåð ãîëîâà çàáîëèò èëè çóá íàïðèìåð,òî âûïåâàþ ïîë òàáëåòêè àíàëüãèíà,÷åðåç 3 ìèí.ñðàçó áîëü ïðîõîäèò!à ñ ìåíñòð.íèêàêèå ñðåäñòâà íå ïîìîãàþò!
|
#27
|
|||
|
|||
òåïåðü çàêîíîìåðíûé âîïðîñ - ñêîëüêî Âàì ëåò, è ÷òî âàì ðàññêàçûâàåò ÓÇÈ è ìàçîê íà ôëîðó?
|
#28
|
|||
|
|||
ìíå 20 ëåò.êîãäà â ñàìûé ïàðâûé ðàç ÿ îáðàòèëàñü â ãåíèêîëîãèþ 2 ãîäà íàçàä ìàçîê íà ôëîðó ïîêàçàë:ñìåøàííàÿ,î÷åíü îáèëüíàÿ+++.íàçíà÷èëè ñå÷è îò âîñïàëåíèÿ.âíóòðü òðèõîïîë è íèñòàòèí,äàëàöèí âàãèíàëüíûé,êëîòðèìàçîë.çàòåì ñäàâàëà ìàçîê â äðóãîé óæå ãåíèêîëîãèè(íåäàâíî)-ãàðäíåðåëà,óðåïëàçìà,ïàïèëëîìàâèðóñ,ïîñåâ íà áàêòåðèîëîãè÷.,õëàìèäèè,ìèêîïëàçìà,trichomonas-íå ÷åãî íå îáíàðóæåíî.ñêàçàëè ìàçîê õîðîøèé.óçè òî÷íî äàííûå íå ìîãîó ñêàçàòü,îñòàëñÿ ó ãåíèêîëîãà-ýíäîêðèíîëîãà.íî ÿè÷íèêè íå óâåëè÷åíû(ïîìíþ,÷òî 4 ñì).ÿ ñðàçó â äâóõ ðàçíûõ ÍÈÈ äåëàëà óçè è àíàëèçû ñäàâàëà,âñ¸ òîæå ñàìîå îäèíàêîâî.
|
#29
|
|||
|
|||
âîñïàëåíèå ìîæåò áûòü ïðè÷èíîé áîëåâîãî ñèíäðîìà, ïîýòîìó òåì áîëåå âàì äîëæíî áûòü èíòåðåñíî, ÷òî åñòü ñåé÷àñ, ñîõðàíÿåòñÿ ëè âîñïàëåíèå â íàñòîÿùåå âðåìÿ. Êîãäà äåëàëè èññëåäîâàíèÿ ïîñëåäíèé ðàç è ÷òî èìåííî ïîëó÷èëè?
|
#30
|
|||
|
|||
ìàçêè è óçè äåëàëà 3 íåäåëè íàçàä.ñêàçàëè,÷òî íèêàêîãî âîñïàëåíèÿ íåò.÷òî èìåííî òàì áûëî íàïèñàíî ñêàçàòü íåìîãó,ò.ê.àíàëèç íà ôëîðó íå ìîãó íàéòè.íå ìîæåò æå âîñïàëåíèå îñòàòüñÿ,åñëè åãî âûëå÷èëè?òåì áîëåå ýòî áûëî 2 ãîäà íàçàä,ïîñëå ýòîãî ÿ áûëà åù¸ ó 2 ðàçíûõ ãåíèêîëîãîâ è íè÷åãî ïëîõîãî îíè íå ãîâîðèëè.è çà÷åì áû ìíå ãîâîðèëè,åñëè ÷òî òî íå òàê,÷òî âñ¸ ÷èñòî íè÷åãî íåò,ìàçîê èäåàëüíûé?!âîñïàëåíèÿ âëàãàëèùà ñêîðåå âñåãî áûëî èç-çà ýðîçèè.ìíå íàçíà÷èëè ñâå÷è,âîñïîëåíèå ïðîøëî,çàòåì ÷åðåç íåäåëþ ïðèæãëè ëàçåðîì ýðîçèþ.à áîëè òàê è îñòàëèñü.íà âîïðîñ,à ÷òî ñ áîëÿìè äåëàòü?îòâåòèëè,÷òî ðîäèøü ïðîéä¸ò!ÿ ñ ýòèì íå ñîãëàñíà(ò.ê.ýòî íå âûíîñèìî áîëüíî,à íå ïðîñòî òåðïèìî),ïîýòîìó ïîøëà ïî äðóãèì âðà÷àì.à êàêèå ñèìïòîìû äîëæíû áûòü ïðè âîñïàëåíèè?
|